
(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - 2
Watch SpaceX launch 119 payloads to orbit from California early on March 30 - 3
Heart disease risk greater for women with a common condition they may not be aware they have - 4
Top 15 Supportable Design Brands Coming out on top - 5
Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
Novo Nordisk cuts Wegovy price in South Africa for a second time
Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
Pfizer says patient dies after receiving hemophilia drug in trial
Allow Innovative Progressions To have a Massive Effect
Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky?
5 Language Learning Applications
The Force of Organic product: 10 Assortments That Improve Your Wellbeing
Why are NASA's Artemis astronauts wearing orange? What are they bringing to space? What to know about the preparation for their moon mission.
6 Asian Urban areas to Visit













